1. In Vivo
  2. >>Outlook
  3. >>Outlook Archive

Business Continuity And Growth Kept In Sharp Focus At J&J Vision Care

 
• By Ashley Yeo

The COVID-19 pandemic dealt a blow to Johnson & Johnson’s Vision Care business, but the company maintained its innovation program and kept customer engagement to the fore. It has started to see a return to positive contact lens buying trends, says Vision Care European business leaders Sandra Rasche and Lisa Ann Hill.

contact lens

Early in the COVID-19 pandemic, Johnson & Johnson’s contact lens business leaders decided to set up regular consumer surveys to gauge the pandemic’s impact on contact lens usage during the lockdowns and quarantine periods. The surveys also allowed the Vision Care business to keep pace with public confidence changes, patients’ ongoing needs and buying habits.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Outlook Archive

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

 
• By Ashley Yeo

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.  

Infographic: Top 100 Pharma Companies

 
• By Lucie Ellis-Taitt

The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.    

Pfizer Leads An Unusual Year For The Scrip 100

 
• By Jessica Merrill

Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.      

Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down

 
• By Jo Shorthouse

What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.

More from Outlook

Investor Optimism Ahead As Big Medtech Proves ‘It’s All About Value’

 
• By Ashley Yeo

Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy

 
• By Joseph Haas

Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.

Big Pharma Headcounts: Obesity Leaders Bulk Up As Others Go Lean

 
• By Andrew McConaghie

As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.